AstriVax Revenue and Competitors
Estimated Revenue & Valuation
- AstriVax's estimated annual revenue is currently $6.2M per year.
- AstriVax's estimated revenue per employee is $155,000
Employee Data
- AstriVax has 40 Employees.
- AstriVax grew their employee count by 82% last year.
AstriVax's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Hepatitis B Program | Reveal Email/Phone |
AstriVax Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 32 | -26% | N/A | N/A |
#2 | $510.1M | 1097 | 31% | $2B | N/A |
#3 | $13.6M | 88 | 44% | N/A | N/A |
#4 | $12.2M | 79 | 0% | N/A | N/A |
#5 | $28.7M | 185 | 5% | N/A | N/A |
#6 | $35.2M | 227 | 8% | N/A | N/A |
#7 | $4M | 26 | -10% | N/A | N/A |
#8 | $10.9M | 70 | 23% | N/A | N/A |
#9 | $10.4M | 67 | 24% | N/A | N/A |
#10 | $6.2M | 40 | 29% | N/A | N/A |
What Is AstriVax?
AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens.
keywords:N/A
N/A
Total Funding
40
Number of Employees
$6.2M
Revenue (est)
82%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Heverlee
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.5M | 40 | 14% | N/A |
#2 | $5.8M | 43 | -7% | N/A |
#3 | $9.5M | 61 | -3% | N/A |
#4 | $8.6M | 66 | 27% | N/A |
#5 | $8.6M | 66 | 6% | N/A |